Please login to the form below
GSK sells Italian research unit to Aptuit
GSK is to sell its Medicines Research Centre in Verona, Italy to Aptuit Inc who will continue to employ all 500 staff who work at the centre
Aptuit will supply GSK with R&D services from the facilities. The acquisition will allow Aptuit to provide integrated development services to its global customers while keeping the existing pool of life science research experts in Italy.
The financial terms of the deal have not been disclosed.
In February 2010, GSK announced plans to cease discovery research in selected neuroscience areas, including depression and pain, to focus on neurodegenerative and neuroinflammatory diseases like Alzheimer's disease, multiple sclerosis and Parkinson's disease. These plans have a direct impact on the Italian R&D facility.
Aptuit specialises in providing contract development and manufacturing services to the pharmaceutical and biotech sectors. This latest acquisition will bring their global portfolio total to 19 locations.
Share
Related Hub content
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
- ONS data reveals significant decrease in COVID-19 antibodies
- Researchers create ‘world’s largest’ database for predicting cancer treatment response
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- ONS data reveals significant decrease in COVID-19 antibodies
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
